ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Remicade (Infliximab) Monoclonal Antibody Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-29Q14464
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Remicade Infliximab Monoclonal Antibody Market Research Report 2023
BUY CHAPTERS

Global Remicade (Infliximab) Monoclonal Antibody Market Research Report 2025

Code: QYRE-Auto-29Q14464
Report
May 2025
Pages:77
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
J & J
Pfizer Inc
Organon
Amgen Inc

Remicade (Infliximab) Monoclonal Antibody Market Size

The global market for Remicade (Infliximab) Monoclonal Antibody was valued at US$ 2920 million in the year 2024 and is projected to reach a revised size of US$ 4253 million by 2031, growing at a CAGR of 5.6% during the forecast period.

Remicade (Infliximab) Monoclonal Antibody Market

Remicade (Infliximab) Monoclonal Antibody Market

Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn"s disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.
The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn"s disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Remicade (Infliximab) Monoclonal Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Remicade (Infliximab) Monoclonal Antibody.
The Remicade (Infliximab) Monoclonal Antibody market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Remicade (Infliximab) Monoclonal Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Remicade (Infliximab) Monoclonal Antibody manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Remicade (Infliximab) Monoclonal Antibody Market Report

Report Metric Details
Report Name Remicade (Infliximab) Monoclonal Antibody Market
Accounted market size in year US$ 2920 million
Forecasted market size in 2031 US$ 4253 million
CAGR 5.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company J & J, Pfizer, Organon, Amgen
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Remicade (Infliximab) Monoclonal Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Remicade (Infliximab) Monoclonal Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Remicade (Infliximab) Monoclonal Antibody Market growing?

Ans: The Remicade (Infliximab) Monoclonal Antibody Market witnessing a CAGR of 5.6% during the forecast period 2025-2031.

What is the Remicade (Infliximab) Monoclonal Antibody Market size in 2031?

Ans: The Remicade (Infliximab) Monoclonal Antibody Market size in 2031 will be US$ 4253 million.

Who are the main players in the Remicade (Infliximab) Monoclonal Antibody Market report?

Ans: The main players in the Remicade (Infliximab) Monoclonal Antibody Market are J & J, Pfizer, Organon, Amgen

What are the Application segmentation covered in the Remicade (Infliximab) Monoclonal Antibody Market report?

Ans: The Applications covered in the Remicade (Infliximab) Monoclonal Antibody Market report are Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s Disease, Other

What are the Type segmentation covered in the Remicade (Infliximab) Monoclonal Antibody Market report?

Ans: The Types covered in the Remicade (Infliximab) Monoclonal Antibody Market report are Brand, Biosimilar

Recommended Reports

Monoclonal Antibodies

Autoimmune Diseases

Inflammatory Disorders

1 Remicade (Infliximab) Monoclonal Antibody Market Overview
1.1 Product Definition
1.2 Remicade (Infliximab) Monoclonal Antibody by Type
1.2.1 Global Remicade (Infliximab) Monoclonal Antibody Market Value Comparison by Type (2024 VS 2031)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Remicade (Infliximab) Monoclonal Antibody by Application
1.3.1 Global Remicade (Infliximab) Monoclonal Antibody Market Value by Application (2024 VS 2031)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Global Remicade (Infliximab) Monoclonal Antibody Market Size Estimates and Forecasts
1.4.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue 2020-2031
1.4.2 Global Remicade (Infliximab) Monoclonal Antibody Sales 2020-2031
1.4.3 Global Remicade (Infliximab) Monoclonal Antibody Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Remicade (Infliximab) Monoclonal Antibody Market Competition by Manufacturers
2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Manufacturers (2020-2025)
2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Remicade (Infliximab) Monoclonal Antibody, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Product Type & Application
2.7 Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Date of Enter into This Industry
2.8 Global Remicade (Infliximab) Monoclonal Antibody Market Competitive Situation and Trends
2.8.1 Global Remicade (Infliximab) Monoclonal Antibody Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Remicade (Infliximab) Monoclonal Antibody Players Market Share by Revenue
2.8.3 Global Remicade (Infliximab) Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Remicade (Infliximab) Monoclonal Antibody Market Scenario by Region
3.1 Global Remicade (Infliximab) Monoclonal Antibody Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Remicade (Infliximab) Monoclonal Antibody Sales by Region: 2020-2031
3.2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Region: 2020-2025
3.2.2 Global Remicade (Infliximab) Monoclonal Antibody Sales by Region: 2026-2031
3.3 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region: 2020-2031
3.3.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region: 2020-2025
3.3.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region: 2026-2031
3.4 North America Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.4.1 North America Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2020-2031)
3.4.3 North America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.5.1 Europe Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Remicade (Infliximab) Monoclonal Antibody Sales by Country (2020-2031)
3.5.3 Europe Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Region
3.6.1 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales by Region (2020-2031)
3.6.3 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.7.1 Latin America Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2020-2031)
3.7.3 Latin America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.8.1 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Sales by Country (2020-2031)
3.8.3 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Type (2020-2031)
4.1.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Type (2020-2025)
4.1.2 Global Remicade (Infliximab) Monoclonal Antibody Sales by Type (2026-2031)
4.1.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Type (2020-2031)
4.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Type (2020-2031)
4.2.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Type (2020-2025)
4.2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Type (2026-2031)
4.2.3 Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Type (2020-2031)
4.3 Global Remicade (Infliximab) Monoclonal Antibody Price by Type (2020-2031)
5 Segment by Application
5.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Application (2020-2031)
5.1.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Application (2020-2025)
5.1.2 Global Remicade (Infliximab) Monoclonal Antibody Sales by Application (2026-2031)
5.1.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Application (2020-2031)
5.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Application (2020-2031)
5.2.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Application (2020-2025)
5.2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Application (2026-2031)
5.2.3 Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Application (2020-2031)
5.3 Global Remicade (Infliximab) Monoclonal Antibody Price by Application (2020-2031)
6 Key Companies Profiled
6.1 J & J
6.1.1 J & J Company Information
6.1.2 J & J Description and Business Overview
6.1.3 J & J Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
6.1.4 J & J Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.1.5 J & J Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Organon
6.3.1 Organon Company Information
6.3.2 Organon Description and Business Overview
6.3.3 Organon Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Organon Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.3.5 Organon Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Company Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Amgen Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.4.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Remicade (Infliximab) Monoclonal Antibody Industry Chain Analysis
7.2 Remicade (Infliximab) Monoclonal Antibody Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Remicade (Infliximab) Monoclonal Antibody Production Mode & Process Analysis
7.4 Remicade (Infliximab) Monoclonal Antibody Sales and Marketing
7.4.1 Remicade (Infliximab) Monoclonal Antibody Sales Channels
7.4.2 Remicade (Infliximab) Monoclonal Antibody Distributors
7.5 Remicade (Infliximab) Monoclonal Antibody Customer Analysis
8 Remicade (Infliximab) Monoclonal Antibody Market Dynamics
8.1 Remicade (Infliximab) Monoclonal Antibody Industry Trends
8.2 Remicade (Infliximab) Monoclonal Antibody Market Drivers
8.3 Remicade (Infliximab) Monoclonal Antibody Market Challenges
8.4 Remicade (Infliximab) Monoclonal Antibody Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
J & J
Pfizer Inc
Organon
Amgen Inc
List of Tables
 Table 1. Global Remicade (Infliximab) Monoclonal Antibody Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Remicade (Infliximab) Monoclonal Antibody Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Remicade (Infliximab) Monoclonal Antibody Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Remicade (Infliximab) Monoclonal Antibody Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Remicade (Infliximab) Monoclonal Antibody Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Remicade (Infliximab) Monoclonal Antibody Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Remicade (Infliximab) Monoclonal Antibody Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Remicade (Infliximab) Monoclonal Antibody, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Product Type & Application
 Table 12. Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Remicade (Infliximab) Monoclonal Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Remicade (Infliximab) Monoclonal Antibody as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Remicade (Infliximab) Monoclonal Antibody Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Remicade (Infliximab) Monoclonal Antibody Sales by Region (2020-2025) & (K Units)
 Table 18. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Region (2020-2025)
 Table 19. Global Remicade (Infliximab) Monoclonal Antibody Sales by Region (2026-2031) & (K Units)
 Table 20. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Region (2026-2031)
 Table 21. Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Region (2020-2025)
 Table 23. Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Region (2026-2031)
 Table 25. North America Remicade (Infliximab) Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2020-2025) & (K Units)
 Table 27. North America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2026-2031) & (K Units)
 Table 28. North America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Remicade (Infliximab) Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Remicade (Infliximab) Monoclonal Antibody Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Remicade (Infliximab) Monoclonal Antibody Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Remicade (Infliximab) Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Remicade (Infliximab) Monoclonal Antibody Sales (K Units) by Type (2020-2025)
 Table 51. Global Remicade (Infliximab) Monoclonal Antibody Sales (K Units) by Type (2026-2031)
 Table 52. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Type (2020-2025)
 Table 53. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Type (2026-2031)
 Table 54. Global Remicade (Infliximab) Monoclonal Antibody Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Remicade (Infliximab) Monoclonal Antibody Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Type (2020-2025)
 Table 57. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Type (2026-2031)
 Table 58. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Remicade (Infliximab) Monoclonal Antibody Sales (K Units) by Application (2020-2025)
 Table 61. Global Remicade (Infliximab) Monoclonal Antibody Sales (K Units) by Application (2026-2031)
 Table 62. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Application (2020-2025)
 Table 63. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Application (2026-2031)
 Table 64. Global Remicade (Infliximab) Monoclonal Antibody Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Remicade (Infliximab) Monoclonal Antibody Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Application (2020-2025)
 Table 67. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Application (2026-2031)
 Table 68. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Application (2026-2031)
 Table 70. J & J Company Information
 Table 71. J & J Description and Business Overview
 Table 72. J & J Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. J & J Remicade (Infliximab) Monoclonal Antibody Product
 Table 74. J & J Recent Developments/Updates
 Table 75. Pfizer Company Information
 Table 76. Pfizer Description and Business Overview
 Table 77. Pfizer Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Pfizer Remicade (Infliximab) Monoclonal Antibody Product
 Table 79. Pfizer Recent Developments/Updates
 Table 80. Organon Company Information
 Table 81. Organon Description and Business Overview
 Table 82. Organon Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Organon Remicade (Infliximab) Monoclonal Antibody Product
 Table 84. Organon Recent Developments/Updates
 Table 85. Amgen Company Information
 Table 86. Amgen Description and Business Overview
 Table 87. Amgen Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Amgen Remicade (Infliximab) Monoclonal Antibody Product
 Table 89. Amgen Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Remicade (Infliximab) Monoclonal Antibody Distributors List
 Table 93. Remicade (Infliximab) Monoclonal Antibody Customers List
 Table 94. Remicade (Infliximab) Monoclonal Antibody Market Trends
 Table 95. Remicade (Infliximab) Monoclonal Antibody Market Drivers
 Table 96. Remicade (Infliximab) Monoclonal Antibody Market Challenges
 Table 97. Remicade (Infliximab) Monoclonal Antibody Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Remicade (Infliximab) Monoclonal Antibody
 Figure 2. Global Remicade (Infliximab) Monoclonal Antibody Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Remicade (Infliximab) Monoclonal Antibody Market Share by Type: 2024 & 2031
 Figure 4. Brand Product Picture
 Figure 5. Biosimilar Product Picture
 Figure 6. Global Remicade (Infliximab) Monoclonal Antibody Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Remicade (Infliximab) Monoclonal Antibody Market Share by Application: 2024 & 2031
 Figure 8. Ankylosing Spondylitis
 Figure 9. Rheumatoid Arthritis
 Figure 10. Crohn’s Disease
 Figure 11. Other
 Figure 12. Global Remicade (Infliximab) Monoclonal Antibody Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Remicade (Infliximab) Monoclonal Antibody Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Remicade (Infliximab) Monoclonal Antibody Sales (2020-2031) & (K Units)
 Figure 15. Global Remicade (Infliximab) Monoclonal Antibody Average Price (US$/Unit) & (2020-2031)
 Figure 16. Remicade (Infliximab) Monoclonal Antibody Report Years Considered
 Figure 17. Remicade (Infliximab) Monoclonal Antibody Sales Share by Manufacturers in 2024
 Figure 18. Global Remicade (Infliximab) Monoclonal Antibody Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Remicade (Infliximab) Monoclonal Antibody Players: Market Share by Revenue in Remicade (Infliximab) Monoclonal Antibody in 2024
 Figure 20. Remicade (Infliximab) Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Remicade (Infliximab) Monoclonal Antibody Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Country (2020-2031)
 Figure 23. North America Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Country (2020-2031)
 Figure 24. United States Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Country (2020-2031)
 Figure 27. Europe Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Region (2020-2031)
 Figure 35. China Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. China Taiwan Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Southeast Asia Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Latin America Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Country (2020-2031)
 Figure 43. Latin America Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Country (2020-2031)
 Figure 44. Mexico Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Brazil Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Argentina Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Country (2020-2031)
 Figure 48. Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Country (2020-2031)
 Figure 49. Turkey Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Saudi Arabia Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. UAE Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Global Sales Market Share of Remicade (Infliximab) Monoclonal Antibody by Type (2020-2031)
 Figure 53. Global Revenue Market Share of Remicade (Infliximab) Monoclonal Antibody by Type (2020-2031)
 Figure 54. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Type (2020-2031)
 Figure 55. Global Sales Market Share of Remicade (Infliximab) Monoclonal Antibody by Application (2020-2031)
 Figure 56. Global Revenue Market Share of Remicade (Infliximab) Monoclonal Antibody by Application (2020-2031)
 Figure 57. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Application (2020-2031)
 Figure 58. Remicade (Infliximab) Monoclonal Antibody Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Remicade Infliximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Remicade infliximab Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Infliximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Infliximab Injection Market Research Report 2024
Global Anti TNF α Monoclonal Antibody Market Insights Forecast to 2030
Adalimumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global TNF Inhibitors for the Treatment of Rheumatoid Arthritis Market Research Report 2024
Global Tumor Necrosis Factor Alpha Inhibitors Market Research Report 2024
Global Recombinant Human Tumor Necrosis Factor α ReceptorⅡ IgG Fc Fusion Protein for Injection Market Research Report 2024
Biosimilar of Remicade Market
Global Arthritis Monoclonal Antibodies Market Research Report 2024
Global Etanercept Solution for Injection Market Research Report 2024
Global Tumor Necrosis Factor TNF Inhibitor Drugs Market Insights Forecast to 2030
Global Ustekinumab Biosimilars Market Research Report 2024
Global Tumor Necrosis Factor Antibody Market Research Report 2024
Global Tumor Necrosis Factor TNF Antagonists Market Research Report 2024
Adalimumab Humira and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Rituximab Biosimilars Market Research Report 2025
Enbrel Etanercept and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Adalimumab Infliximab And Etanercept Biosimilars Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions